Novel Fecal Biomarker for Irritable Bowel Syndrome

Novel Fecal Biomarker for Irritable Bowel Syndrome - Novel Biomarker for IBS

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057593

Enrollment

100

Registered

2025-10-01

Start date

2025-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with Irritable Bowel Syndrome and Healthy Subjects

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: IBS patients: meet Rome IV criteria for IBS and do not meet the exclusion criteria Healthy subjects: those who do not meet Rome IV criteria and have no other complications

Exclusion criteria

Exclusion criteria: IBS patients: have histories of abdominal surgeries and/or colorectal diseases other than IBS Healthy controls: have other serious complications

Design outcomes

Primary

Measure	Time frame
Hydroxysteroid 11-beta dehydrogenase 2 (HSD11B2) gene expression level in the fecal samples	—

Secondary

Measure	Time frame
Gut microbiome and metabolites in the fecal samples	—

Countries

Japan

Contacts

Public ContactMotoyori Kanazawa

Tohoku University Hospital Division of Psychosomatic Medicine

motoyori.kanazawa.d4@tohoku.ac.jp022-717-7327

Outcome results